glp-1 medications approved for type 2 diabetes 2025 In the phase 3 ACHIEVE-1 trial, published in June 2025, the oral small-molecule receptor agonist orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with Complete Guide to GLP-1 Medications

This reduction in heat-generating capacity and insulation leads to increased cold sensitivity, particularly in the extremities

[PubMed] [Google Scholar] 464.Wang Y., Egan J.M., Raygada M., Nadiv O., Roth J., Montrose-Rafizadeh C

And from mechanistic standpoint, everything we talked about previously about what estrogen does and how changing estrogen changes our metabolism, I think you can start to piece together like why this might be a good idea

10.1016/j.appet.2011.04.011 54

and regulation of right ventricular systolic pressure and remodeling of the pulmonary arteries in pulmonary hypertension, as well as their effects in pulmonary hypertension outside group 2, to name just a few

Results will provide the first controlled data on this approach